Walter M. Stadler to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications Walter M. Stadler has written about TOR Serine-Threonine Kinases.
Connection Strength
0.365
-
Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case. Pathology. 2021 Oct; 53(6):790-793.
Score: 0.177
-
Predictive markers in advanced renal cell carcinoma. Semin Oncol. 2013 Aug; 40(4):459-64.
Score: 0.105
-
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
Score: 0.042
-
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
Score: 0.022
-
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
Score: 0.019